On Friday, Terns Pharmaceuticals Inc (NASDAQ: TERN) opened lower -5.80% from the last session, before settling in for the closing price of $6.55. Price fluctuations for TERN have ranged from $3.51 to $11.40 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -20.00% over the past five years. Company’s average yearly earnings per share was noted 4.51% at the time writing. With a float of $62.16 million, this company’s outstanding shares have now reached $64.58 million.
Let’s look at the performance matrix of the company that is accounted for 66 employees. In terms of profitability, gross margin is 47.35%, operating margin of -7562.78%, and the pretax margin is -6641.75%.
Terns Pharmaceuticals Inc (TERN) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Terns Pharmaceuticals Inc is 24.96%, while institutional ownership is 71.53%. The most recent insider transaction that took place on Sep 12 ’24, was worth 4,999,995. In this transaction Director of this company bought 476,190 shares at a rate of $10.50, taking the stock ownership to the 476,190 shares. Before that another transaction happened on Sep 10 ’24, when Company’s Chief Financial Officer sold 10,000 for $11.00, making the entire transaction worth $110,000. This insider now owns 91,940 shares in total.
Terns Pharmaceuticals Inc (TERN) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.29 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.29) by 0. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.33 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 4.51% per share during the next fiscal year.
Terns Pharmaceuticals Inc (NASDAQ: TERN) Trading Performance Indicators
Check out the current performance indicators for Terns Pharmaceuticals Inc (TERN). In the past quarter, the stock posted a quick ratio of 32.99.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.18, a number that is poised to hit -0.31 in the next quarter and is forecasted to reach -1.37 in one year’s time.
Technical Analysis of Terns Pharmaceuticals Inc (TERN)
Terns Pharmaceuticals Inc (NASDAQ: TERN) saw its 5-day average volume 1.41 million, a positive change from its year-to-date volume of 1.28 million. As of the previous 9 days, the stock’s Stochastic %D was 12.47%. Additionally, its Average True Range was 0.49.
During the past 100 days, Terns Pharmaceuticals Inc’s (TERN) raw stochastic average was set at 5.25%, which indicates a significant decrease from 16.57% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 52.59% in the past 14 days, which was lower than the 80.88% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.03, while its 200-day Moving Average is $7.14. Nevertheless, the first resistance level for the watch stands at $6.49 in the near term. At $6.82, the stock is likely to face the second major resistance level. The third major resistance level sits at $7.12. If the price goes on to break the first support level at $5.86, it is likely to go to the next support level at $5.56. Assuming the price breaks the second support level, the third support level stands at $5.23.
Terns Pharmaceuticals Inc (NASDAQ: TERN) Key Stats
There are currently 84,939K shares outstanding in the company with a market cap of 493.67 million. Presently, the company’s annual sales total 0 K according to its annual income of -90,210 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -22,740 K.
